Ian Jacobson

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.